ARAY - Accuray Incorporated
5.10 0.00 (0.00%)
After hours: 5:36PM EDT
| Previous Close | 5.05 |
| Open | 5.05 |
| Bid | 4.55 x 100 |
| Ask | 5.10 x 1600 |
| Day's Range | 4.95 - 5.10 |
| 52 Week Range | 3.60 - 6.15 |
| Volume | 211,996 |
| Avg. Volume | 767,664 |
| Market Cap | 434.996M |
| Beta | 2.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks•28 days ago
Accuray Radixact Picked by India's Apollo for Cancer Treatment
Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.
- Zacks•29 days ago
Accuray's CyberKnife Treats First Patient at Erasmus MC
Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.
- Zacks•29 days ago
Accuray Banks on Acquisition & Partnership Amid Competition
Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.
- Zacks•last month
Accuray Gains on Radixact Unit, Solid Geographical Foothold
Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).
- Zacks•last month
Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
- Market Realist•2 months ago
How Accuray Has Performed Financially
In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.
Market Realist•2 months agoHow Much Is Accuray’s Target Market Expected to Grow?
To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.
Market Realist•2 months agoWhat Analysts Recommend for Accuray in February 2018
Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.
- Market Realist•2 months ago
A Look at Accuray’s Therapy Systems
Accuray’s (ARAY) CyberKnife systems are robotic systems that treat cancerous tumors through the delivery of radiosurgery. Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types. Based on a CT scanner platform, the Tomo therapy systems provide continuous delivery of radiation from 360 degrees around the patient or from beam angles specified by the clinician.
- Zacks•2 months ago
Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•3 months ago
AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.
- Zacks•3 months ago
Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.
- Zacks•3 months ago
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.
- Zacks•3 months ago
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
- Zacks•3 months ago
Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
- Zacks•3 months ago
Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top
In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.
- Zacks•3 months ago
Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.
- Zacks•3 months ago
McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View
Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.
- Zacks•3 months ago
Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid
Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.
Market Realist•3 months agoSirtex Medical: Varian Medical Systems’ Latest Acquisition
Sirtex Medical Systems is an Australia-based life sciences company with a presence around the globe. The company is focused on interventional oncology therapies and is a global leader in radioembolization. Radioembolization is a minimally invasive therapy for the treatment of liver cancer.
- Zacks•3 months ago
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.
- Zacks•3 months ago
4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now
Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.
- Zacks•3 months ago
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
- Zacks•3 months ago
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.
- Zacks•3 months ago
Stryker (SYK) Beats Earnings and Revenue Estimates in Q4
Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.
